TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7918123

Group type: EXPERIMENTAL
Intervention: Sequential treatment: three courses of neoadjuvant chemotherapy with cisplatin (100 mg/m2 i.v. d 1) and 5‐fluorouracil (1000 mg/m2/days 1‐5 by continuous i.v. infusion every 3 weeks) followed by conventional radiotherapy of 65‐70 Gy.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment: cisplatin (100 mg/m2 on days 1, 22, 43) given simultaneously with conventional radiotherapy of 65‐70 Gy.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Simultaneous treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sequential treatment
Number of subjects: 93

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 93
Study: 2460431

Group type: EXPERIMENTAL
Intervention: Cockroach antigen immunotherapy (CRa‐IT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control immunotherapy (control-IT)
Number of subjects: 28
Study: 29611504

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo (similar placebo tablet)
Number of subjects: 250
Study: 28286095

Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 141

Group type: COMPARATOR
Intervention: White-light (WL) endoscopy
Number of subjects: 141
Study: 25790454

Group type: EXPERIMENTAL
Intervention: Dry-needling and exercise
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham dry-needling and exercise
Number of subjects: 80
Study: 23834882

Group type: EXPERIMENTAL
Intervention: Interactive educational seminar on antibiotic prescription for respiratory infections
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 171
Study: 21997904

Group type: EXPERIMENTAL
Intervention: Saline irrigation plus separate budesonide nasal spray (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Saline irrigation mixed with budesonide nasal spray (group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline irrigation alone (control group A)
Number of subjects: 60
Study: 18477935

Group type: EXPERIMENTAL
Intervention: rhGH (0.2 mg/kg/day) and propranolol (to decrease heart rate by 15%) for > or = 15 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rhGH/propranolol
Number of subjects: 15
Study: 16503537

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine and 20 microg/ml morphine (group L)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine and 20 microg/ml morphine (group R)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine and 20 microg/ml morphine (group B)
Number of subjects: 90
Study: 14551548

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine solution infusion catheter
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Saline infusion catheter
Number of subjects: 42

Group type: COMPARATOR
Intervention: No catheter (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both catheter groups (bupivacaine and saline)
Number of subjects: 42
Study: 10620552

Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered peritoneal dialysis fluid (TB; 38 mmol/L of bicarbonate; pH 7.3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-buffered peritoneal dialysis fluid (TBL; 25 mmol/L of bicarbonate/15 mmol/L of lactate; pH 7.3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Acidic lactate-buffered peritoneal dialysis fluid (PD4; 40 mmol/L of lactate; pH 5.2)
Number of subjects: 15
Study: 8711846

Group type: EXPERIMENTAL
Intervention: Rovamycin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Amox-clav
Number of subjects: 111
Study: 8042334

Group type: EXPERIMENTAL
Intervention: Rigid sclerotherapy
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Flexible sclerotherapy
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Paravariceal sclerotherapy
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Intravariceal sclerotherapy
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Combined sclerotherapy with splenectomy and devascularization
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Sclerotherapy sessions repeated every 2 weeks
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: Surgery after continued bleeding post-sclerotherapy
Number of subjects: 1452

Group type: COMPARATOR
Intervention: Different modalities of sclerotherapy
Number of subjects: 1452
Study: 3043289

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30782886

Group type: EXPERIMENTAL
Intervention: TRAM/DKP 75/25 mg
Number of subjects: 654

Group type: COMPARATOR
Intervention: TRAM/paracetamol 75/650 mg
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 28285318

Group type: EXPERIMENTAL
Intervention: 10 mg bupivacaine (Group S1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 15 mg bupivacaine (Group S2)
Number of subjects: 60
Study: 25483566

Group type: EXPERIMENTAL
Intervention: Hepatitis A/B coadministered with MenACWY-CRM
Number of subjects: 252

Group type: COMPARATOR
Intervention: MenACWY-CRM only
Number of subjects: 252

Group type: COMPARATOR
Intervention: Hepatitis A/B only
Number of subjects: 252
Study: 24090821

Group type: EXPERIMENTAL
Intervention: Collaborative care (CC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 183
Study: 20350671

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (SM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No-intervention (NI)
Number of subjects: 15
Study: 18348601

Group type: EXPERIMENTAL
Intervention: XR‐NTX 380 mg
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: XR‐NTX 190 mg
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 16682719

Group type: EXPERIMENTAL
Intervention: CSF (Colony-Stimulating Factors)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Prophylactic CSF
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy regimens
Number of subjects: 1
Study: 12664385

Group type: EXPERIMENTAL
Intervention: PEG-EL1 (Klean-Prep)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: PEG-EL2 (Endofalk)
Number of subjects: 185

Group type: COMPARATOR
Intervention: NaP (Fleet Phospho-Soda)
Number of subjects: 185
Study: 10630444

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched polymeric diet (42% of amino acid composition)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard low-glutamine polymeric diet (4% of amino acid composition)
Number of subjects: 18
Study: 9013375

Group type: EXPERIMENTAL
Intervention: Terazosin alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Terazosin and finasteride
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Finasteride alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Finasteride and terazosin
Number of subjects: 48
Study: 1349294

Group type: EXPERIMENTAL
Intervention: 10% dextrose infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion study in persons with mild hypothyroidism (saline or 10% dextrose)
Number of subjects: 0
Study: 6530305

Group type: EXPERIMENTAL
Intervention: Alteration of nicotine level (specific dosage and duration not provided)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study: 30772385

Group type: EXPERIMENTAL
Intervention: Lixisenatide + Basal Insulin (BI)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Sulfonylurea + Basal Insulin (BI)
Number of subjects: 181
Study: 29718092

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 668
Study: 28963845

Group type: EXPERIMENTAL
Intervention: Kangle Decoction at 0.5 dose bid for 8 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cialis at 10 mg qd alt for 8 weeks
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Kangle Decoction
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cialis
Number of subjects: 79
Study: 25070961

Group type: EXPERIMENTAL
Intervention: ropinirole + physical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo + physical therapy
Number of subjects: 0
Study: 22551324

Group type: EXPERIMENTAL
Intervention: topical nipradilol
Number of subjects: 146

Group type: COMPARATOR
Intervention: topical timolol
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: topical β-blocker (nipradilol or timolol)
Number of subjects: 146
Study: 20386073

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zidovudine 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zidovudine 300 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amdoxovir
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amdoxovir plus Zidovudine 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amdoxovir plus Zidovudine 300 mg
Number of subjects: 24
Study: 18001618

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17136932

Group type: EXPERIMENTAL
Intervention: Nurse-led heart failure clinic
Number of subjects: 0
Study: 11856098

Group type: EXPERIMENTAL
Intervention: Thin loop TURP
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thick loop TUVRP
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study: 10099977

Group type: EXPERIMENTAL
Intervention: Low-dose step-up FSH with IUI
Number of subjects: 97

Group type: COMPARATOR
Intervention: Conventional FSH with IUI
Number of subjects: 97
Study: 7486431

Group type: EXPERIMENTAL
Intervention: Polyglyconate (Maxon) suture
Number of subjects: 225

Group type: COMPARATOR
Intervention: Nylon suture
Number of subjects: 225
Study: 2359575

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring and perinatal nursing support
Number of subjects: 45

Group type: COMPARATOR
Intervention: Education group
Number of subjects: 45
Study: 7380690

Group type: EXPERIMENTAL
Intervention: autologous reinfusion of approximately 900 ml of freeze-preserved blood
Number of subjects: 11

Group type: COMPARATOR
Intervention: sham reinfusion of 50 ml of saline
Number of subjects: 11

Group type: COMPARATOR
Intervention: control hematologic levels after erythrocythemia (C3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: before phlebotomy (C1)
Number of subjects: 11

Group type: COMPARATOR
Intervention: following restoration of normocythemia (C2)
Number of subjects: 11
Study: 30190165

Group type: EXPERIMENTAL
Intervention: 20-mg TAK-063
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 28284477

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35 (8 × 108 colony‐forming units, n=48), twice daily for 4 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (n=46), twice daily for 4 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (n=46)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35 (n=48)
Number of subjects: 94
Study: 26352940

Group type: EXPERIMENTAL
Intervention: Paracetamol mixed with a liquid meal administered by a nasogastric feeding tube
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paracetamol mixed with a liquid meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paracetamol in the aqueous phase of the meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paracetamol in the solid bolus of the meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paracetamol as a post prandial marker
Number of subjects: 12
Study: 23357167

Group type: EXPERIMENTAL
Intervention: Ig apheresis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 21259004

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), with doses doubled at week 4 if LDL-C target not achieved, for 8 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 mg/day (TS 1) and 10 mg/day (TS ≥ 2), for 8 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atorvastatin 5 to 10 mg (TS 1) or 10 to 20 mg (TS ≥ 2) for 8 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 39
Study: 19458017

Group type: EXPERIMENTAL
Intervention: High energy supplementation (an extra 475 kcal/d)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no high energy supplementation)
Number of subjects: 106
Study: 17294706

Group type: EXPERIMENTAL
Intervention: Traditional educational
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PRECEDE Model
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual health center care (Control)
Number of subjects: 160
Study: 15646947

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (T)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 36
Study: 11443562

Group type: EXPERIMENTAL
Intervention: Intravenous palivizumab (15 mg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intravenous palivizumab (15 mg/kg) with aerosolized ribavirin
Number of subjects: 21
Study: 9164909

Group type: EXPERIMENTAL
Intervention: Patients with early development of aortic regurgitation
Number of subjects: 315
Study: 7963081

Group type: EXPERIMENTAL
Intervention: Sugar expectancy condition (mothers told their children received a large dose of sugar)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition (mothers told their sons received a placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Sugar expectancy condition
Number of subjects: 35
Study: 3445799

Group type: EXPERIMENTAL
Intervention: MLCu375
Number of subjects: 2353

Group type: COMPARATOR
Intervention: Nova-T
Number of subjects: 2353
Study: 28666095

Group type: EXPERIMENTAL
Intervention: Early Enteral Immunonutrition (EEIN)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 78
Study: 27325341

Group type: EXPERIMENTAL
Intervention: Booklet-only decision aid
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Booklet with DVD decision aid
Number of subjects: 147
Study: 24315293

Group type: EXPERIMENTAL
Intervention: Atropine 0.5%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Atropine 0.1%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Atropine 0.01%
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Overall increase in SE
Number of subjects: 400
Study: 24260170

Group type: COMPARATOR
Intervention: Green tea consumption
Number of subjects: 4808

Group type: COMPARATOR
Intervention: Rock tea consumption
Number of subjects: 4808
Study: 19882171

Group type: EXPERIMENTAL
Intervention: rAd‐p53 combined with fSRT
Number of subjects: 40

Group type: COMPARATOR
Intervention: fSRT alone
Number of subjects: 40
Study: 18247220

Group type: EXPERIMENTAL
Intervention: Electrical Injury (EI) patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Chronic Pain (CP) patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: Traumatic Brain Injury (TBI) patients
Number of subjects: 79
Study: 17138773

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg nightly for 4 weeks
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo nightly for 4 weeks
Number of subjects: 410
Study: 12955028

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sex steroid treatment (testosterone for men, oestrogen/progestin for women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11144863

Group type: EXPERIMENTAL
Intervention: Endurance exercise (50 min of cycle ergometry at 70‐110% of critical power)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (no cycling performed)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 8
Study: 9200306

Group type: EXPERIMENTAL
Intervention: Interferon mono-therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged interferon therapy
Number of subjects: 0
Study: 7694879

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (with or without azathioprine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study: 3083211

Group type: EXPERIMENTAL
Intervention: 250 mg/d of sorbinil
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29661477

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) <60 mm Hg
Number of subjects: 3417

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) 60-69 mm Hg
Number of subjects: 3417

Group type: COMPARATOR
Intervention: Diastolic blood pressure (DBP) 80-89 mm Hg
Number of subjects: 3417

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) <70 mm Hg
Number of subjects: 3417

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP) ≥70 mm Hg with systolic blood pressure (SBP) <120 mm Hg
Number of subjects: 3417
Study: 27431451

Group type: EXPERIMENTAL
Intervention: Bilateral arm remote ischemic postconditioning (RIPC) twice a day for 6 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bilateral arm remote ischemic postconditioning (RIPC)
Number of subjects: 100
Study: 24343119

Group type: EXPERIMENTAL
Intervention: Tight blood pressure control (systolic BP target <130 mm Hg)
Number of subjects: 1111

Group type: COMPARATOR
Intervention: Standard blood pressure control (systolic BP target <140 mm Hg)
Number of subjects: 1111
Study: 22804619

Group type: EXPERIMENTAL
Intervention: 20-G cannula
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 22-G cannula
Number of subjects: 80
Study: 21127697

Group type: EXPERIMENTAL
Intervention: Safflower seed extract (SSE) 70 mg/day for 12 weeks
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 92
Study: 18492267

Group type: EXPERIMENTAL
Intervention: Daily interruption of sedation (DIS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Sedation algorithms (SA)
Number of subjects: 74
Study: 16014059

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 24 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 40
Study: 12457373

Group type: EXPERIMENTAL
Intervention: Cost methods used in economic evaluations
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Statistical analysis of cost data
Number of subjects: 45
Study: 10621928

Group type: EXPERIMENTAL
Intervention: Red wine (5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 0
Study: 7594127

Group type: COMPARATOR
Intervention: Usual-protein group
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Low-protein group
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Very-low-protein group
Number of subjects: 840
Study: 2030877

Group type: EXPERIMENTAL
Intervention: Pipelle endometrial sampling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pipelle biopsy
Number of subjects: 40
Study: 7141389

Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29943060

Group type: EXPERIMENTAL
Intervention: 3DP
Number of subjects: 45

Group type: COMPARATOR
Intervention: VIR
Number of subjects: 45

Group type: COMPARATOR
Intervention: MDCT
Number of subjects: 45
Study: 28934531

Group type: EXPERIMENTAL
Intervention: Sleep extension (EXT; 1.5‐hour increase in time in bed from HAB)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prescribed habitual sleep (HAB; sleep time set to match baseline)
Number of subjects: 76
Study: 27179184

Group type: EXPERIMENTAL
Intervention: Strengths-based case management (SBCM) service
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Treatment-as-usual PRS (Control)
Number of subjects: 1276
Study: 24399094

Group type: EXPERIMENTAL
Intervention: Genetic counseling session for approximately 10 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (received a booklet for general diabetes prevention)
Number of subjects: 0
Study: 22460438

Group type: EXPERIMENTAL
Intervention: Blastocyst group (thawed and cultured in sequential media until blastocyst stage)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Cleavage group (thawed embryos in cleavage stage)
Number of subjects: 134
Study: 19687336

Group type: EXPERIMENTAL
Intervention: PLD 30 mg/m2 followed by docetaxel 60 mg/m2 every 21 days (n = 378)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 (n = 373)
Number of subjects: 751
Study: 17578957

Group type: EXPERIMENTAL
Intervention: LMA with propofol + 7.5 ng/mL remifentanil (LMA-PR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LT with propofol + 7.5 ng/mL remifentanil (LT-PR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LMA with propofol + saline (LMA-P)
Number of subjects: 24

Group type: COMPARATOR
Intervention: LT with propofol + saline (LT-P)
Number of subjects: 24
Study: 15279343

Group type: EXPERIMENTAL
Intervention: 16 mg lornoxicam
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 11773166

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m² plus Irinotecan 175 mg/m²
Number of subjects: 92

Group type: COMPARATOR
Intervention: Raltitrexed 3 mg/m²
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oxaliplatin/irinotecan after cross-over
Number of subjects: 92

Group type: COMPARATOR
Intervention: Raltitrexed after cross-over
Number of subjects: 92
Study: 9419196

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg orally twice daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 8127329

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol (50 mg per day)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: beta carotene (20 mg per day)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: beta carotene
Number of subjects: 29133

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29133
Study: 2916913

Group type: EXPERIMENTAL
Intervention: Immediate postoperative physical therapy
Number of subjects: 115

Group type: COMPARATOR
Intervention: No physical therapy (Control)
Number of subjects: 115